MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study
John Mascarenhas(Tisch Hospital), Vikas Gupta(Indian Institute of Technology Kanpur), Francesco Passamonti(University of Milan), Moshe Talpaz(University of Michigan), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Gozde Colak(Morpho (United States)), Pietro Taverna, Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alex R. Chang, Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Sandra Klein(Universitätsmedizin Greifswald), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Marina Kremyanskaya(Tisch Cancer Institute), Gabriela Hobbs(Massachusetts General Hospital), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Srđan Verstovšek(Unknown), Timothy Devos(Rega Institute for Medical Research), Dong Chen(Mayo Clinic in Arizona), Francesca Palandri(Istituto Oncologico Romagnolo), Ron Hoffman, Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 13
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k